Choose a language and wait for the translated text.
Shots:
Hansoh Pharma has entered into a strategic collaboration & license agreement with Roche, marking their second ADC collaboration, to advance a broad ADC portfolio across multiple cancer types, comprising 2 preclinical Hansoh ADC programs & multiple ADC programs based on Roche-proposed targets powered by Hansohβs proprietary ADC technology platform
As per the deal, Hansoh will receive $400M upfront & a $110M first anniversary payment, and is eligible for potentially >$15B in development, regulatory & commercialization milestones, plus tiered royalties on potential future sales; Hansoh also has the option to select up to 2 programs & contribute to their development outside Greater China in return for incremental upside from their US commercialization
Hansoh will lead early development of the programs up to the completion of global P-Ia trials, after which Roche will be responsible for further development worldwide (excl. the Chinese Mainland, Hong Kong, Macau & Taiwan), while Hansoh retains all rights to develop, register & commercialize the programs in these regions
Ref: Hansoh Pharma | Image: Hansoh Pharma & Roche | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
The post Hansoh Pharma and Roche Enter Over $15B Strategic Collaboration and License Agreement to Advance Novel ADC Portfolio appeared first on PharmaShots.
